Potential conflict of interest: Nothing to report.
Autoimmune, Cholestatic and Biliary Disease
Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in utah children: Epidemiology and natural history
Article first published online: 13 AUG 2013
Copyright © 2013 by the American Association for the Study of Liver Diseases
Volume 58, Issue 4, pages 1392–1400, October 2013
How to Cite
Deneau, M., Jensen, M. K., Holmen, J., Williams, M. S., Book, L. S. and Guthery, S. L. (2013), Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in utah children: Epidemiology and natural history. Hepatology, 58: 1392–1400. doi: 10.1002/hep.26454
The project described in this article was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences (National Institutes of Health) through grant 8UL1TR000105 (formerly UL1RR025764). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
- Issue published online: 1 OCT 2013
- Article first published online: 13 AUG 2013
- Accepted manuscript online: 17 MAY 2013 08:14AM EST
- Manuscript Accepted: 5 APR 2013
- Manuscript Received: 10 FEB 2013
The epidemiology and natural history of pediatric primary sclerosing cholangitis (PSC), autoimmune sclerosing cholangitis (ASC), and autoimmune hepatitis (AIH) are not well characterized. Using multiple, overlapping search strategies followed by a detailed records review, we identified all cases of pediatric PSC, ASC, AIH, and inflammatory bowel disease (IBD) in a geographically isolated region of the United States. We identified 607 cases of IBD, 29 cases of PSC, 12 cases of ASC, and 44 cases of AIH. The mean age at diagnosis was 13.0 years for PSC, 11.3 years for ASC, and 9.8 years for AIH. The incidence and prevalence of PSC, ASC, and AIH were 0.2 and 1.5 cases, 0.1 and 0.6 cases, and 0.4 and 3.0 cases per 100,000 children, respectively. The mean duration of follow-up was 5.9 years. The probability of developing complicated liver disease within 5 years of the diagnosis of liver disease was 37% [95% confidence interval (CI) = 21%-58%] for PSC, 25% (95% CI = 7%-70%) for ASC, and 15% (95% CI = 7%-33%) for AIH. The 5-year survival rates with the native liver were 78% (95% CI = 54%-91%) for PSC, 90% (95% CI = 47%-99%) for ASC, and 87% (95% CI = 71%-95%) for AIH. Cholangiocarcinoma developed in 2 of the 29 PSC patients (6.9%). PSC occurred in 9.9% of patients with ulcerative colitis (UC) and in 0.6% of patients with Crohn's disease (CD). ASC occurred in 2.3% of UC patients and 0.9% of CD patients. AIH occurred in 0.4% of UC patients and in 0.3% of CD patients. Liver disease occurred in 39 of 607 IBD patients (6.4%) overall. Conclusion: Immune-mediated liver diseases are important sources of morbidity in children. Using a population-based design, this study quantifies the burden and natural history of immune-mediated liver disease in children. (Hepatology 2013;58:1392–1400)